z-logo
open-access-imgOpen Access
Lamotrigine for people with borderline personality disorder: a RCT
Author(s) -
Mike Crawford,
Rahil Sanatinia,
Barbara Barrett,
Gillian Cunningham,
Oliver Dale,
Poushali Ganguli,
Geoff Lawrence-Smith,
Verity C. Leeson,
Fenella Lemonsky,
Georgia Lykomitrou-Matthews,
Alan Montgomery,
Richard Morriss,
Jasna Munjiza,
Carol Paton,
Iwona Skorodzien,
Vineet Singh,
Wei Tan,
Peter Tyrer,
J. Reilly
Publication year - 2018
Publication title -
health technology assessment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.426
H-Index - 126
eISSN - 2046-4924
pISSN - 1366-5278
DOI - 10.3310/hta22170
Subject(s) - borderline personality disorder , lamotrigine , medicine , psychiatry , randomized controlled trial , mood , schizoaffective disorder , placebo , psychosis , alternative medicine , pathology , epilepsy
No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Despite this, people with this condition are frequently prescribed psychotropic medications and often with considerable polypharmacy. Preliminary studies have indicated that mood stabilisers may be of benefit to people with BPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom